Revvity Inc (RVTY)

$111.52 +1.38 (1.25%)
Market Cap 11.78B
Revenue (ttm) 2.76B
Net Income (ttm) 270.39M
EPS (ttm) N/A
PE Ratio 21.80
Forward PE 19.66
Profit Margin 9.81%
Debt to Equity Ratio 0.44
Volume 2,050,906
Avg Vol 1,404,642
Day's Range N/A - N/A
Shares Out 113.38M
Stochastic %K 74%
Beta 1.05
Analysts Sell
Price Target $114.13

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and sc...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 663 6900
Address:
77 4th Avenue, Waltham, United States
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 14 at 1:48 PM
$RVTY Yesterday confirmed the breakout w 2.6M shares $118-$120 next
0 · Reply
LaineyPatton59
LaineyPatton59 Jan. 14 at 12:03 PM
$RVTY quality name, trend confirmation if it keeps higher lows with steady institutional flow
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 7:58 PM
$RVTY $118 next …. Great conference potential partnerships w Tech companies to use their Signal software
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 13 at 2:47 PM
$RVTY
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 2:43 PM
$RVTY Conference today @ 12:45PM will add more gas as they talk about SIGNAL ….
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 2:38 PM
$RVTY $118 next…then $130 Load em up granny them wagons
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 13 at 1:25 PM
$RVTY (+10.6% pre) Revvity schedules earnings call and raises guidance above range https://ooc.bz/l/89499
0 · Reply
Tokenist
Tokenist Jan. 13 at 11:31 AM
🧪🚀 $RVTY rips premarket on a Q4 revenue beat Revvity ($RVTY) is popping after dropping better-than-expected Q4 numbers. The company said Q4 revenue will hit ~$772M, topping Wall Street’s ~$760M estimate and signaling renewed momentum in life sciences + diagnostics. 📊 Key highlights: • Q4 revenue: $772M (+6% YoY, +4% organic) • Full-year 2025 revenue: ~$2.86B, also above estimates • Full-year EPS now expected to beat the top end of prior guidance 💥 The market liked it. Shares jumped ~8% premarket as investors price in stronger demand across pharma, biotech, diagnostics, and research labs worldwide. 👀 Full earnings drop Feb 2, with management presenting at JPM Healthcare today. Bottom line: Guidance beats + raised EPS = buyers step in.
1 · Reply
theflynews
theflynews Jan. 13 at 12:25 AM
Closing Bell Movers: Revvity up 9% on strong outlook - $RVTY - https://thefly.com/permalinks/entry.php/RVTYid4269755?1768263883C38
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 12 at 10:45 PM
$RVTY $118 next …. They guided higher for Q4 which means they will most certainly up guidance for 2026 as SIGNAL dominates medical AI ….
0 · Reply
Latest News on RVTY
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:56 PM EST - 1 day ago

Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Jan 13, 2026, 5:51 AM EST - 1 day ago

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Revvity says it will exceed 2025 profit forecast range

Jan 12, 2026, 5:10 PM EST - 2 days ago

Revvity says it will exceed 2025 profit forecast range

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Jan 12, 2026, 4:15 PM EST - 2 days ago

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Jan 9, 2026, 8:00 AM EST - 5 days ago

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 27 days ago

Revvity to Present at J.P. Morgan Healthcare Conference

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Dec 16, 2025, 8:00 AM EST - 4 weeks ago

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 12:53 PM EST - 6 weeks ago

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 11:38 AM EST - 2 months ago

Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 10:11 AM EST - 2 months ago

Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Nov 10, 2025, 8:00 AM EST - 2 months ago

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Nov 10, 2025, 7:45 AM EST - 2 months ago

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Oct 28, 2025, 9:32 AM EDT - 2 months ago

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Revvity to Present at Upcoming Investor Conferences

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Revvity to Present at Upcoming Investor Conferences

Revvity: Software Momentum And Screening Offset China Weakness

Oct 27, 2025, 12:56 PM EDT - 2 months ago

Revvity: Software Momentum And Screening Offset China Weakness

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 12:47 PM EDT - 2 months ago

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Oct 27, 2025, 7:06 AM EDT - 2 months ago

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Revvity Announces Financial Results for the Third Quarter of 2025

Oct 27, 2025, 6:00 AM EDT - 2 months ago

Revvity Announces Financial Results for the Third Quarter of 2025

Revvity Board Declares Quarterly Dividend

Oct 23, 2025, 4:05 PM EDT - 2 months ago

Revvity Board Declares Quarterly Dividend

Revvity Showcases Progress with Purpose in 2025 Impact Report

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Revvity Showcases Progress with Purpose in 2025 Impact Report

Revvity to Hold Earnings Call on Monday, October 27, 2025

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Revvity to Hold Earnings Call on Monday, October 27, 2025

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

Oct 2, 2025, 8:00 AM EDT - 3 months ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

SNY

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Sep 29, 2025, 8:00 AM EDT - 3 months ago

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Sep 22, 2025, 8:00 AM EDT - 4 months ago

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 9, 2025, 5:31 PM EDT - 4 months ago

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 10:40 AM EDT - 4 months ago

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Aug 6, 2025, 8:00 AM EDT - 5 months ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Jul 28, 2025, 2:47 PM EDT - 6 months ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 1:40 PM EDT - 6 months ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

Jul 28, 2025, 12:25 PM EDT - 6 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 11:59 AM EDT - 6 months ago

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 6 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ATAI

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 8:09 AM EDT - 6 months ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 7:39 AM EDT - 6 months ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 28, 2025, 6:00 AM EDT - 6 months ago

Revvity Announces Financial Results for the Second Quarter of 2025

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jul 7, 2025, 8:00 AM EDT - 6 months ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Jun 2, 2025, 8:00 AM EDT - 8 months ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 19, 2025, 8:00 AM EDT - 8 months ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

May 9, 2025, 10:35 AM EDT - 8 months ago

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 11:49 AM EDT - 9 months ago

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Apr 28, 2025, 9:14 AM EDT - 9 months ago

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Revvity beats quarterly estimates on steady demand for medical equipment

Apr 28, 2025, 7:32 AM EDT - 9 months ago

Revvity beats quarterly estimates on steady demand for medical equipment

Revvity Announces Financial Results for the First Quarter of 2025

Apr 28, 2025, 6:00 AM EDT - 9 months ago

Revvity Announces Financial Results for the First Quarter of 2025

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Apr 23, 2025, 8:00 AM EDT - 9 months ago

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Revvity Fuels the Future of Cancer Science with New Research Solutions

Apr 22, 2025, 8:00 AM EDT - 9 months ago

Revvity Fuels the Future of Cancer Science with New Research Solutions

RSSS

Revvity to Hold Earnings Call on Monday, April 28, 2025

Apr 3, 2025, 8:00 AM EDT - 10 months ago

Revvity to Hold Earnings Call on Monday, April 28, 2025

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Mar 20, 2025, 1:00 PM EDT - 10 months ago

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 14 at 1:48 PM
$RVTY Yesterday confirmed the breakout w 2.6M shares $118-$120 next
0 · Reply
LaineyPatton59
LaineyPatton59 Jan. 14 at 12:03 PM
$RVTY quality name, trend confirmation if it keeps higher lows with steady institutional flow
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 7:58 PM
$RVTY $118 next …. Great conference potential partnerships w Tech companies to use their Signal software
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 13 at 2:47 PM
$RVTY
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 2:43 PM
$RVTY Conference today @ 12:45PM will add more gas as they talk about SIGNAL ….
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 2:38 PM
$RVTY $118 next…then $130 Load em up granny them wagons
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 13 at 1:25 PM
$RVTY (+10.6% pre) Revvity schedules earnings call and raises guidance above range https://ooc.bz/l/89499
0 · Reply
Tokenist
Tokenist Jan. 13 at 11:31 AM
🧪🚀 $RVTY rips premarket on a Q4 revenue beat Revvity ($RVTY) is popping after dropping better-than-expected Q4 numbers. The company said Q4 revenue will hit ~$772M, topping Wall Street’s ~$760M estimate and signaling renewed momentum in life sciences + diagnostics. 📊 Key highlights: • Q4 revenue: $772M (+6% YoY, +4% organic) • Full-year 2025 revenue: ~$2.86B, also above estimates • Full-year EPS now expected to beat the top end of prior guidance 💥 The market liked it. Shares jumped ~8% premarket as investors price in stronger demand across pharma, biotech, diagnostics, and research labs worldwide. 👀 Full earnings drop Feb 2, with management presenting at JPM Healthcare today. Bottom line: Guidance beats + raised EPS = buyers step in.
1 · Reply
theflynews
theflynews Jan. 13 at 12:25 AM
Closing Bell Movers: Revvity up 9% on strong outlook - $RVTY - https://thefly.com/permalinks/entry.php/RVTYid4269755?1768263883C38
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 12 at 10:45 PM
$RVTY $118 next …. They guided higher for Q4 which means they will most certainly up guidance for 2026 as SIGNAL dominates medical AI ….
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 5:37 PM
AI drug discovery just got a heavyweight boost — here’s why it matters. 🚀 $RVTY is partnering with $LLY to bring TuneLab AI models into Signals Xynthetica, aiming to enable secure, federated drug discovery at scale through this collaboration. See how this partnership could expand AI-driven discovery capabilities 👉 https://www.zacks.com/stock/news/2815577/rvty-eli-lilly-partner-to-expand-access-to-ai-drug-discovery-models?cid=sm-stocktwits-2-2815577-teaser-28488&ADID=SYND_STOCKTWITS_TWEET_2_2815577_TEASER_28488
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 4:37 PM
$RVTY partners with Eli Lilly — a big move in AI drug discovery! 🤝 The collaboration brings Lilly's TuneLab models to Revvity's Signals Xynthetica platform, enhancing AI-driven drug discovery and boosting potential recurring software revenues. 🚀 Discover the full potential of this partnership here 👉 https://www.zacks.com/stock/news/2815577/rvty-eli-lilly-partner-to-expand-access-to-ai-drug-discovery-models?cid=sm-stocktwits-2-2815577-body-28474&ADID=SYND_STOCKTWITS_TWEET_2_2815577_BODY_28474
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 12 at 3:50 PM
$RVTY Prepare for a massive cup and handle breakout
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 9 at 5:38 PM
$RVTY Cup and handle breakout JP conf Tuesday Jan 13
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 7 at 4:30 PM
$RVTY My number 1 healthcare pick for 2026
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 5 at 8:37 PM
$RVTY $110 next
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 1 at 7:39 PM
$RVTY January 16 calls keep getting bought
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Dec. 30 at 1:53 AM
$RVTY This hardly ever has any option activity however 1600 contracts on the January 16 $115 calls What’s interesting is they have a conference w JP Morgan on January 13…..
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 11:20 PM
$RVTY RSI: 35.65, MACD: -0.0256 Vol: 3.04, MA20: 100.20, MA50: 96.81 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:11 PM
Barclays has updated their rating for Revvity ( $RVTY ) to Overweight with a price target of 115.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:30 PM
Wells Fargo has adjusted their stance on Revvity ( $RVTY ), setting the rating to Equal-Weight with a target price of 102 → 107.
0 · Reply
Estimize
Estimize Dec. 15 at 1:03 PM
Wall St is expecting 1.54 EPS for $RVTY Q4 [Reporting 01/29 BMO] http://www.estimize.com/intro/rvty?chart=historical&metric_name=eps&utm_co
0 · Reply